← Leaderboards
Takeshi Kurita
Northwestern University At Chicago
$5,224,195
Attributed
$5,224,195
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $919.3K · FY2009–22$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,224,195 · 6
By mechanism
R01$3,140,186 · 2
P50$1,324,650 · 1
R21$429,000 · 1
U54$330,350 · 1
P01$9 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Elizabeth Anne Hibler$781,788
Others in their field
Top investigators on “Woman”
- Chanza Baytop · Westat, Inc.$271,217,917
- Lawrence Corey · Fred Hutchinson Cancer Center$252,110,127
- Wafaa M. El-Sadr · Columbia University Health Sciences$232,152,340
- Myron S Cohen · Family Health International$208,921,087
- Barbara Driver · Westat, Inc.$190,429,693
- Judith S. Currier · University Of California Los Angeles$149,317,678
Research focus
WomanMolecularBenignPlayInhibitor/AntagonistHormonesResponseGrowthIncidenceSignal TransductionIn VivoPathogenesisUterine FibroidsLeiomyomaGenesApoptosisEtiologyClinical TrialsOvarianOverexpressionExcisionRegulationUterusIn Vitro
Grant awards (21)
In vivo Identification of stem cells in MED12 mutant leiomyoma$195,000
R21 · FY2022 · HD · contact PI
In vivo Identification of stem cells in MED12 mutant leiomyoma$234,000
R21 · FY2020 · HD · contact PI
Project 3: Medically-based Protection of the Ovarian Reserve Against Anti-Cancer$340,374
P50 · FY2017 · HD · contact PI
Project 3: Medically-based Protection of the Ovarian Reserve Against Anti-Cancer$331,241
P50 · FY2016 · HD · contact PI
Project 3: Medically-based Protection of the Ovarian Reserve Against Anti-Cancer$330,285
P50 · FY2015 · HD · contact PI
Project 3: Medically-based Protection of the Ovarian Reserve Against Anti-Cancer$322,750
P50 · FY2014 · HD · contact PI
Molecular Etiology of Cervicovaginal Adenosis by in Utero Hormone Exposure$295,015
R01 · FY2014 · CA · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$220,459
R01 · FY2014 · HD · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$81,028
R01 · FY2014 · HD · contact PI
Project 3: Medically-based Protection of the Ovarian Reserve Against Anti-Cancer$330,350
U54 · FY2013 · HD · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$295,234
R01 · FY2013 · HD · contact PI
Molecular etiology of cervicovaginal adenosis by in utero hormone exposure$288,528
R01 · FY2013 · CA · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$311,100
R01 · FY2012 · HD · contact PI
Molecular etiology of cervicovaginal adenosis by in utero hormone exposure$306,944
R01 · FY2012 · CA · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$311,100
R01 · FY2011 · HD · contact PI
Molecular etiology of cervicovaginal adenosis by in utero hormone exposure$306,944
R01 · FY2011 · CA · contact PI
Core B: Tissue Procurement and Cell Culture Core$3
P01 · FY2011 · HD · contact PI
Xenograft Study on Growth-Control of Human Uterine Leiomyomata$407,396
R01 · FY2010 · HD · contact PI
Molecular etiology of cervicovaginal adenosis by in utero hormone exposure$316,438
R01 · FY2010 · CA · contact PI
Core B: Tissue Procurement and Cell Culture Core$4
P01 · FY2010 · HD · contact PI
Core B: Tissue Procurement and Cell Culture Core$2
P01 · FY2009 · HD · contact PI